Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period

AIDS

Volumn 27, Issue 12, 2013, Pages 1899-1909

  Kyeyune, Fred ^a   Nankya, Immaculate ^a,b   Metha, Samar ^a   Akao, Juliet ^a   Ndashimye, Emmanuel ^a   Tebit, Denis M ^b   Rodriguez, Benigno ^b   Kityo, Cissy ^a   Salata, Robert A ^b   Mugyenyi, Peter ^a   Arts, Eric J ^a,b  

^a JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral treatment; Drug resistance; HIV 1; Resource limited setting; Subtypes; Uganda

Indexed keywords

ABACAVIR; CYTIDINE DERIVATIVE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; DRUG TREATMENT FAILURE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; PATIENT CARE; PRIORITY JOURNAL; TREATMENT OUTCOME; UGANDA; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; TREATMENT FAILURE; UGANDA; VIRAL LOAD;

EID: 84884386998     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283610ec7     Document Type: Article

References (44)

1. Mermin J, Were W, Ekwaru JP, Moore D, Downing R, Behumbiize P, et al. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet 2008; 371:752-759.
2. Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med 2012; 9:e1001290.
3. Ojikutu B, Makadzange AT, Gaolathe T. Scaling up ART treatment capacity: lessons learned from South Africa, Zimbabwe, and Botswana. Curr Infect Dis Rep 2008; 10:69-73.
4. Taegtmeyer M, Chebet K. Overcoming challenges to the implementation of antiretroviral therapy in Kenya. Lancet Infect Dis 2002; 2:51-53.
5. Wood R, Lawn SD. Should the CD4 threshold for starting ART be raised? Lancet 2009; 373:1314-1316.
6. Crowley S, Rollins N, Shaffer N, Guerma T, Vitoria M, Lo YR. New WHO HIV treatment and prevention guidelines. Lancet 2009; 375:874-875.
7. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:409-417.
8. Simcock M, Sendi P, Ledergerber B, Keller T, Schupbach J, Battegay M, et al. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off? Antivir Ther 2006; 11:305-314.
9. Hamers RL, Derdelinckx I, van VM, Stevens W, Rinke de Wit TF, Schuurman R. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther 2008; 13:625-639.
10. Richard N, Juntilla M, Abraha A, Demers K, Paxinos E, Galovich J, et al. High prevalence of antiretroviral resistance in treated Ugandans infected with nonsubtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2004; 20:355-364.
11. Diaz RS, Sucupira MC, Vergara TR, Brites C, Bianco RD, Bonasser FF, et al. HIV-1 resistance testing influences treatment decision-making. Braz J Infect Dis 2010; 14:489-494.
12. Badolato R, Schumacher RF, Rodella E, Gargiulo F, Torti C, Notarangelo LD, et al. Genotyping for guiding drug choice in human immunodeficiency virus-infected children failing multiple antiretroviral treatment regimens. Pediatr Infect Dis J 2005; 24:747-749.
13. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2012; 2:a007161.
14. Mansky LM. HIV mutagenesis and the evolution of antiretroviral drug resistance. Drug Resist Updat 2002; 5:219-223.
15. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18:156-163.
16. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246:1155-1158.
17. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2:e112.
18. Gao Y, Paxinos E, Galovich J, Troyer R, Baird H, Abreha M, et al. Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors. J Virol 2004; 78:5390-5401.
19. Wainberg MA, Brenner BG. The impact of HIV genetic polymorphisms and subtype differences on the occurrence of resistance to antiretroviral drugs. Mol Biol Int 2012; 2012:256982.
20. Bocket L, Cheret A, Deuffic-Burban S, Choisy P, Gerard Y, de lT X, et al. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther 2005; 10:247-254.
21. Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, et al. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009; 48:1296-1305.
22. Easterbrook PJ, Smith M, Mullen J, O'Shea S, Chrystie I, de Ruiter RA, et al. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc 2010; 13:4.
23. Soares EA, Santos AF, Sousa TM, Sprinz E, Martinez AM, Silveira J, et al. Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS One 2007; 2:e730.
24. Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, et al. Patterns of HIV-1 drug resistance after firstline antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 2012; 54:1660-1669.
25. Hamers RL, Sigaloff KC, Kityo C, Mugyenyi P, de Wit TF. HIV-1 drug resistance in antiretroviral-naive patients in sub-Saharan Africa. Lancet Infect Dis 2013; 13:196-197.
26. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, et al. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. J Infect Dis 2012; 205:1739-1744.
27. Ssemwanga D, Ndembi N, Lyagoba F, Bukenya J, Seeley J, Vandepitte J, et al. HIV type 1 subtype distribution, multiple infections, sexual networks, and partnership histories in female sex workers in Kampala, Uganda. AIDS Res Hum Retroviruses 2012; 28:357-365.
28. Kaleebu P, Ross A, Morgan D, Yirrell D, Oram J, Rutebemberwa A, et al. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS 2001; 15:293-299.
29. Richard N, Juntilla M, Abraha A, Demers K, Paxinos E, Galovich J, et al. High prevalence of antiretroviral resistance in treated Ugandans infected with nonsubtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2004; 20:355-364.
30. Troyer RM, Lalonde MS, Fraundorf E, Demers KR, Kyeyune F, Mugyenyi P, et al. A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda. AIDS Res Hum Retroviruses 2008; 24:235-250.
31. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11:750-759.
32. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002; 185:1244-1250.
33. Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007; 195:1177-1180.
34. Abraha A, Nankya IL, Gibson R, Demers K, Tebit DM, Johnston E, et al. CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic. J Virol 2009; 83:5592-5605.
35. Quinones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, Albright JL, Vanham G, et al. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol 2000; 74:9222-9233.
36. Troyer RM, Collins KR, Abraha A, Fraundorf E, Moore DM, Krizan RW, et al. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 2005; 79:9006-9018.
37. Blaak H, van't Wout AB, Brouwer M, Hooibrink B, Hovenkamp E, Schuitemaker H. In vivo HIV-1 infection of CD45RA(R) CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proc Natl Acad Sci U S A 2000; 97:1269-1274.
38. Lassen KG, Lobritz MA, Bailey JR, Johnston S, Nguyen S, Lee B, et al. Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog 2009; 5:e1000377.
39. Kaleebu P, Nankya IL, Yirrell DL, Shafer LA, Kyosiimire-Lugemwa J, Lule DB, et al. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr 2007; 45:28-33.
40. Reynolds SJ, Sendagire H, Newell K, Castelnuovo B, Nankya I, Kamya M, et al. Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda. BMC Infect Dis 2012; 12:381.
41. Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised noninferiority trial. Lancet 2010; 375:123-131.
42. Lyagoba F, Dunn DT, Pillay D, Kityo C, Robertson V, Tugume S, et al. Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring. J Acquir Immune Defic Syndr 2010; 55:277-283.
43. Iglesias-Ussel MD, Casado C, Yuste E, Olivares I, Lopez-Galindez C. In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J Gen Virol 2002; 83 (Pt 1):93-101.
44. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak MA, et al. Enhanced fidelity of 3TC selected mutant HIV-1 reverse transcriptase. Science 1996; 271:1282-1285.